User profiles for Alexandru-Emil Matei

Alexandru-Emil Matei

PhD Student, FAU Erlangen-Nürnberg
Verified email at uk-erlangen.de
Cited by 834

Targeting TGF-β signaling for the treatment of fibrosis

AH Györfi, AE Matei, JHW Distler - Matrix biology, 2018 - Elsevier
Transforming growth factor-β (TGF-β) is widely recognized as a core pathway of fibrosis.
Inhibition of TGF-β signaling may thus offer potential for antifibrotic therapies. Long-term …

PU. 1 controls fibroblast polarization and tissue fibrosis

…, S Uebe, M Luber, A Soare, A Ekici, S Weber, AE Matei… - Nature, 2019 - nature.com
Fibroblasts are polymorphic cells with pleiotropic roles in organ morphogenesis, tissue
homeostasis and immune responses. In fibrotic diseases, fibroblasts synthesize abundant …

[HTML][HTML] The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis

A Zehender, J Huang, AH Györfi, AE Matei… - Nature …, 2018 - nature.com
Uncontrolled activation of TGFβ signaling is a common denominator of fibrotic tissue
remodeling. Here we characterize the tyrosine phosphatase SHP2 as a molecular checkpoint for …

68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre …

…, K Tascilar, AT Müller, A Atzinger, AE Matei… - The Lancet …, 2021 - thelancet.com
Background Interstitial lung disease (ILD) is the most common cause of death in systemic
sclerosis. To date, the progression of systemic sclerosis-associated ILD is judged by the …

[HTML][HTML] Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT

…, SC Fakhouri, AH Györfi, A Atzinger, AE Matei… - European Journal of …, 2023 - Springer
Purpose Myocardial fibrosis (MF) is a factor of poor prognosis in systemic sclerosis (SSc).
Direct in-vivo visualization of fibroblast activation as early readout of MF has not been feasible …

Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation

AH Györfi, AE Matei, M Fuchs, C Liang… - Journal of Experimental …, 2021 - rupress.org
Transforming growth factor-β (TGFβ) is a key mediator of fibroblast activation in fibrotic
diseases, including systemic sclerosis. Here we show that Engrailed 1 (EN1) is reexpressed in …

Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis

…, H Zhu, A Jüngel, L Summa, YN Li, AE Matei… - Science translational …, 2020 - science.org
Aberrant activation of fibroblasts with progressive deposition of extracellular matrix is a key
feature of systemic sclerosis (SSc), a prototypical idiopathic fibrotic disease. Here, we …

Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs

AE Matei, CW Chen, L Kiesewetter, AH Györfi… - Annals of the …, 2019 - ard.bmj.com
Objectives Fibrosis is a complex pathophysiological process involving interplay between
multiple cell types. Experimental modelling of fibrosis is essential for the understanding of its …

[HTML][HTML] Dynamic changes in O-GlcNAcylation regulate osteoclast differentiation and bone loss via nucleoporin 153

YN Li, CW Chen, T Trinh-Minh, H Zhu, AE Matei… - Bone Research, 2022 - nature.com
Bone mass is maintained by the balance between osteoclast-induced bone resorption and
osteoblast-triggered bone formation. In inflammatory arthritis such as rheumatoid arthritis (RA)…

Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators

AE Matei, C Beyer, AH Györfi, A Soare… - Annals of the …, 2018 - ard.bmj.com
Objectives Stimulators of soluble guanylate cyclase (sGC) are currently investigated in
clinical trials for the treatment of fibrosis in systemic sclerosis (SSc). In this study, we aim to …